...
首页> 外文期刊>Psychopharmacology >Chronic treatment with the selective NOP receptor antagonist (Nphe 1, Arg 14, Lys 15)N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats.
【24h】

Chronic treatment with the selective NOP receptor antagonist (Nphe 1, Arg 14, Lys 15)N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats.

机译:用选择性NOP受体拮抗剂(Nphe 1,Arg 14,Lys 15)N / OFQ-NH 2(UFP-101)进行的慢性治疗可逆转大鼠中不可预测的慢性轻度应激的行为和生化作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: The present study was designed to assess the antidepressant effects of UFP-101, a selective nociceptin/orphanin FQ peptide (NOP) receptor antagonist, in a validated animal model of depression: the chronic mild stress (CMS). MATERIALS AND METHODS AND RESULTS: UFP-101 (5, 10 and 20 nmol/rat; i.c.v., once a day for 21 days) dose- and time-dependently reinstated sucrose consumption in stressed animals without affecting the same parameter in non-stressed ones. In the forced swimming test, UFP-101 reduced immobility of stressed rats from day 8 of treatment. After a 3-week treatment, rats were killed for biochemical evaluations. UFP-101 abolished increase in serum corticosterone induced by CMS and reverted changes in central 5-HT/5-HIAA ratio. The behavioural and biochemical effects of UFP-101 mimicked those of imipramine, the reference antidepressant drug, administered at the dose of 15 mg/kg (i.p.). Co-administration of nociceptin/orphanin FQ (5 nmol/rat, from day 12 to 21) prevented the effects of UFP-101. Brain-derived neurotrophic factor mRNA and protein in hippocampus were not reduced by CMS nor did UFP-101 modify these parameters. DISCUSSION AND CONCLUSION: This study demonstrated that chronic treatment with UFP-101 produces antidepressant-like effects in rats subjected to CMS supporting the proposal that NOP receptors represent a candidate target for the development of innovative antidepressant drugs.
机译:引言:本研究旨在评估UFP-101(一种选择性伤害感受器/孤啡肽FQ肽(NOP)受体拮抗剂)在经过验证的抑郁症动物模型:慢性轻度应激(CMS)中的抗抑郁作用。材料,方法和结果:UFP-101(5、10和20 nmol /大鼠; icv,每天一次,持续21天)在应激动物中剂量和时间依赖性地恢复了蔗糖的消耗,而没有影响非应激动物中的相同参数。在强迫游泳测试中,UFP-101从治疗的第8天起减少了压力大的大鼠的活动能力。治疗3周后,处死大鼠进行生化评估。 UFP-101消除了CMS诱导的血清皮质酮增加,并恢复了中枢5-HT / 5-HIAA比的变化。 UFP-101的行为和生化作用模仿了以15 mg / kg(腹膜内)剂量给药的参比抗抑郁药丙咪嗪的作用。 Nociceptin / orphanin FQ(5nmol /大鼠,从第12天到21天)的共同给药可预防UFP-101的作用。 CMS并没有降低海马中脑源性神经营养因子的mRNA和蛋白,UFP-101也没有改变这些参数。讨论与结论:这项研究表明,用UFP-101进行的慢性治疗在CMS大鼠中产生抗抑郁样作用,支持了NOP受体代表开发新型抗抑郁药的候选靶点的提议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号